This trend was found to have its origin in the decreasing laser power density arriving at the crater bottom and thereby weakened the shock wave generated in the crater. As the crater deepened, the declining trend of the intensity

appeared to level off as a result of compensation of the decreasing laser power density by the enhanced plasma confinement at increasing crater depth. Meanwhile, the result also reveals the significant contribution of the He-assisted excitation process to the doped hydrogen and deuterium emission intensities, leading to similar crater-depth dependent variation patterns in contrast to that associated with the surface water, with growing dominance of this common feature at the later stage of the buy BTSA1 plasma Tamatinib Fosdium expansion. Therefore, a carefully chosen set of gate delay and gate width which are properly adapted to the crater-depth dependent behavior of the emission intensity may produce the desired intrinsic emission data for quantitative depth profiling of H impurity trapped inside the zircaloy wall. (C) 2009 American Institute of Physics. [doi: 10.1063/1.3224864]“
“Background: Human immunodeficiency

virus (HIV) infection is widely considered a contraindication for cardiac transplantation. However, with the newer anti-retroviral drugs, the estimated 10-year Survival after seroconversion is exceeds 90%. This case series describes the intermediate range outcome of HIV-positive cardiac transplant recipients.

Methods: A retrospective analysis of 1679 cardiac

transplant patients was undertaken to identify, HIV-positive recipients.

Results: Seven patients were identified. Five (4 men) were diagnosed P505-15 with HIV before transplantation and 2 patients seroconverted after transplantation. Dilated cardiomyopathy was the indication for transplant in all patients. The 5 HIV recipients were aged 42 8 years, and time after HIV seroconversion averaged 9.5 years. All underwent cardiac transplantation as high-risk candidates. The CD4 count was 554 +/- 169 cells/mu l, and viral load was undetectable in all patients at the time of transplantation. Two patients seroconverted to HIV-positive status at I and 7 years after transplant. No AIDS-defining illness was observed in any patient before or after transplant. Six patients received highly active anti-retroviral therapy. Viral load remained low in the presence of immunosuppression. All patients are alive with a follow-up from transplant of 57 +/- 78.9 months.

Conclusion: Excellent intermediate term outcome is noted in carefully selected HIV-positive patients. No significant AIDS-related infections or complications occurred. J Heart Lung Transplant 2009;28: 667-9. Copyright (C) 2009 by the International Society for Heart and Lung Transplantation.